{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T23:10:46Z","timestamp":1662937846487},"reference-count":20,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2019,5,22]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line treatments for various psychiatric disorders. SSRIs offer an improved side effect profile compared to older treatments, which improves patients\u2019 adherence and quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Report:<\/jats:title><jats:p>Here we discuss a case of an uncommon, but a distressing side effect of citalopram. A 76-year old woman was referred to the psychiatry clinic for bizarre behavior. The patient was diagnosed with behavioral variant frontotemporal dementia and was started on citalopram 20 mg and aripiprazole 5 mg daily. At 3.5 months the patient complained of diffuse hair thinning on her scalp. Citalopram was considered the offending agent and was discontinued. Within a few months, the patient regained most of her hair. Although drug-induced alopecia is common among other SSRIs, it is relatively rare with citalopram.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Conclusion:<\/jats:title><jats:p>Early recognition, withdrawal of offending agent, and reassurance to the patient that hair loss is reversible can help alleviate patient distress and avoid relapse.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1574886314666190215115857","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T11:55:53Z","timestamp":1550231753000},"page":"167-170","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Citalopram-Associated Alopecia: A Case Report and Brief Literature Review"],"prefix":"10.2174","volume":"14","author":[{"given":"Joshua","family":"Hekmatjah","sequence":"first","affiliation":[{"name":"Western Michigan University, Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinza","family":"Tareen","sequence":"additional","affiliation":[{"name":"Michigan State University, College of Human Medicine, Lansing, MI, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqiya Shama","family":"Tareen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Western Michigan University, Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jad.2014.11.008","volume":"173","author":"Popovic D.","year":"2015","unstructured":"Popovic D, Vieta E, Fornaro M, Perugi G. J Affect Disord, Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants.,, 2015, 173,, 211-215,","journal-title":"J Affect Disord"},{"key":"ref=2","author":"Baldwin DS","year":"","unstructured":"Baldwin DS. The importance of long-term tolerability in achieving recovery. Int J Psychiatry Clin Pract 2006; 10(sup1): 31-7., , ,","journal-title":"The importance of long-term tolerability in achieving recovery Int J Psychiatry Clin Pract 2006; 10(sup1): 31-7"},{"key":"ref=3","first-page":"392","volume":"148","author":"Jenike M.A.","year":"1991","unstructured":"Jenike MA. Am J Psychiatry, Severe hair loss associated with fluoxetine use.,, 1991, 148,, 392-,","journal-title":"Am J Psychiatry"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1345\/aph.18346","volume":"33","author":"Gautam M.","year":"1999","unstructured":"Gautam M. Ann Pharmacother, Alopecia due to psychotropic medications.,, 1999, 33,, 631-637,","journal-title":"Ann Pharmacother"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clindermatol.2011.11.014","volume":"31","author":"Bliss S.A.","year":"2013","unstructured":"Bliss SA, Warnock JK. Clin Dermatol, Psychiatric medications: Adverse cutaneous drug reactions.,, 2013, 31,, 101-109,","journal-title":"Clin Dermatol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10401230009147085","volume":"12","author":"Mercke Y.","year":"2000","unstructured":"Mercke Y, Sheng H, Khan T, Lippmann S. Ann Clin Psychiatry, Hair loss in psychopharmacology.,, 2000, 12,, 35-42,","journal-title":"Ann Clin Psychiatry"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-4632.1999.tb00004.x","volume":"38","author":"Ruiz-Doblado S.","year":"1999","unstructured":"Ruiz-Doblado S, Carrizosa A, Garcia-Hernandez MJ, Rodriguez-Pichardo A. Int J Dermatol, Selective serotonin re-uptake inhibitors (SSRIs) and alopecia areata.,, 1999, 38,, 798-799,","journal-title":"Int J Dermatol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/09546634.2013.768761","volume":"25","author":"Abedini H.","year":"2014","unstructured":"Abedini H, Farshi S, Mirabzadeh A, Keshavarz S. J Dermatolog Treat, Antidepressant effects of citalopram on treatment of alopecia areata in patients with major depressive disorder.,, 2014, 25,, 153-155,","journal-title":"J Dermatolog Treat"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4088\/PCC.v02n0208d","volume":"2","author":"Gupta S.","year":"2000","unstructured":"Gupta S, Masand PS. Prim Care Companion J Clin Psychiatry, Citalopram and hair loss.,, 2000, 2,, 61-62,","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/pds.1270","volume":"15","author":"Hedenmalm K.","year":"2006","unstructured":"Hedenmalm K, Sundstr\u00f6m A, Spigset O. Pharmacoepidemiol Drug Saf, Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs).,, 2006, 15,, 719-725,","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/070674379504000624","volume":"40","author":"Seifritz E.","year":"1995","unstructured":"Seifritz E, Hatzinger M, M\u00fcller MJ, Hemmeter U. Can J Psychiatry, Hair loss associated with fluoxetine but not with citalopram.,, 1995, 40,, 362-,","journal-title":"Can J Psychiatry"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"Naranjo C.A.","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM. Clin Pharmacol Ther, A method for estimating the probability of adverse drug reactions.,, 1981, 30,, 239-245,","journal-title":"Clin Pharmacol Ther"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1177\/070674379303800113","volume":"38","author":"Potter W.Z.","year":"1993","unstructured":"Potter WZ, Ketter TA. Can J Psychiatry, Pharmacological issues in the treatment of bipolar disorder: Focus on mood-stabilizing compounds.,, 1993, 38,, S51-S56,","journal-title":"Can J Psychiatry"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/07853890.2016.1180426","volume":"48","author":"Lin R.L.","year":"2016","unstructured":"Lin RL, Garibyan L, Kimball AB, Drake LA. Ann Med, Systemic causes of hair loss.,, 2016, 48,, 393-402,","journal-title":"Ann Med"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0033-3182(91)72085-9","volume":"32","author":"Warnock J.K.","year":"1991","unstructured":"Warnock JK. Psychosomatics, Psychotropic medication and drug-related alopecia.,, 1991, 32,, 149-152,","journal-title":"Psychosomatics"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-4362.1995.tb01556.x","volume":"34","author":"Pillans P.J.","year":"1995","unstructured":"Pillans PJ, Woods DJ. Int J Dermatol, Drug\u2010Associated Alopecia.,, 1995, 34,, 149-158,","journal-title":"Int J Dermatol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000369409","volume":"47","author":"Guzm\u00e1n-S\u00e1nchez D.","year":"2015","unstructured":"Guzm\u00e1n-S\u00e1nchez D, Asz-Sigall D. Curr Probl Dermatol, Alopecias due to drugs and other skin and systemic disorders.,, 2015, 47,, 97-106,","journal-title":"Curr Probl Dermatol"},{"key":"ref=18","author":"Goldstein BJ","year":"","unstructured":"Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12(4_suppl): 55-S87, , ,","journal-title":"Selective serotonin reuptake inhibitors in the treatment of affective disorders-III Tolerability, safety and pharmacoeconomics J Psychopharmacol 1998; 12(4_suppl): 55-S87"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00023210-199708040-00005","volume":"8","author":"Rebora A.","year":"1997","unstructured":"Rebora A. CNS Drugs, Changes in growth and distribution of hair associated with psychotropic drug use.,, 1997, 8,, 323-334,","journal-title":"CNS Drugs"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/PCC.v03n0105","volume":"3","author":"Ferguson J.M.","year":"2001","unstructured":"Ferguson JM. Prim Care Companion J Clin Psychiatry, SSRI antidepressant medications: Adverse effects and tolerability.,, 2001, 3,, 22-27,","journal-title":"Prim Care Companion J Clin Psychiatry"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T22:56:12Z","timestamp":1662936972000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170021\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5,22]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886314666190215115857","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}